Desvenlafaxine: A therapeutic option for treatment of menopausal hot flashes

被引：1
作者：
Archer, David F. [1 ]
机构：
[1] Eastern Virginia Med Sch, Dept Obstet & Gynecol, Norfolk, VA 23507 USA
来源：
MATURITAS | 2010年 / 66卷 / 01期
关键词：
NOREPINEPHRINE REUPTAKE INHIBITOR; ASYMPTOMATIC POSTMENOPAUSAL WOMEN; VASOMOTOR SYMPTOMS; MESSENGER-RNA; SEROTONIN; SUCCINATE; FLUSHES; ANTIDEPRESSANTS; PATHOPHYSIOLOGY; HYPOTHALAMUS;
D O I：
10.1016/j.maturitas.2010.02.007
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
引用
收藏
页码：1 / 2
页数：2
相关论文
共 36 条
[1]   Non-estrogenic approaches for the treatment of climacteric symptoms [J].
Albertazzi, P. .
CLIMACTERIC, 2007, 10 :115-120
[2]  
Archer D.F., 2009, American Journal of Obstetrics and Gynecology, V200, p238.
[3]   The role of serotonin in hot flushes [J].
Berendsen, HHG .
MATURITAS, 2000, 36 (03) :155-164
[4]   Use of Gabapentin in Patients Experiencing Hot Flashes [J].
Brown, Jamie N. ;
Wright, Betsy R. .
PHARMACOTHERAPY, 2009, 29 (01) :74-81
[5]   Use of Antidepressants for Management of Hot Flashes [J].
Carroll, Dana G. ;
Kelley, Kristi W. .
PHARMACOTHERAPY, 2009, 29 (11) :1357-1374
[6]  
Carroll DG, 2006, AM FAM PHYSICIAN, V73, P457
[7]   Exercise to reduce vasomotor and other menopausal symptoms: A review [J].
Daley, A. J. ;
Stokes-Lampard, H. J. ;
MacArthur, C. .
MATURITAS, 2009, 63 (03) :176-180
[8]   Understanding the pathophysiology of vasomotor symptoms (hot flushes and night sweats) that occur in perimenopause, menopause, and postmenopause life stages [J].
Deecher, D. C. ;
Dorries, K. .
ARCHIVES OF WOMENS MENTAL HEALTH, 2007, 10 (06) :247-257
[9]   Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor [J].
Deecher, Darlene C. ;
Beyer, Chad E. ;
Johnston, Grace ;
Bray, Jenifer ;
Shah, S. ;
Abou-Gharbia, M. ;
Andree, Terrance H. .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 318 (02) :657-665
[10]   Physiology of thermoregulatory dysfunction and current approaches to the treatment of vasomotor symptoms [J].
Deecher, DC .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2005, 14 (04) :435-448
1234